{"disease":{"id":"squamous-cell-carcinoma-of-esophagus","name":"Squamous cell carcinoma of esophagus","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"pembrolizuma","indication_name":"Squamous cell carcinoma of esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03096054","title":"A CR-UK Phase I Trial of LY3143921","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"Cancer Research UK","has_results":false},{"nct_id":"NCT04196075","title":"The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03762564","title":"Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT01212822","title":"Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":true},{"nct_id":"NCT04713891","title":"A Study of KF-0210 in Advanced Solid Tumors Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Keythera Pharmaceuticals (Australia) Pty Ltd","has_results":false},{"nct_id":"NCT03993353","title":"Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"University of California, San Diego","has_results":true},{"nct_id":"NCT03307941","title":"Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Jules Bordet Institute","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}